Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

About the MayzentConnect programme.

 

Dedicated patient support

MayzentConnect offers dedicated support to patients with secondary progressive multiple sclerosis (SPMS) with active disease and healthcare professionals throughout the MAYZENT journey. Novartis Pharmaceuticals gives those who enrol in the programme unique access to a wide range of services, including specialised medical testing and an experienced nurse team. The programme recognises that multiple sclerosis (MS) services and patients with SPMS with active disease have unique needs and is designed to offer personalised support in conjunction with the usual medical care given by your hospital’s MS team.

MayzentConnect is offered as a package deal, developed and funded by Novartis Pharmaceuticals UK Ltd. MayzentConnect is for NHS patients who are receiving MAYZENT or for whom the prescribing decision has been made. A service level agreement is required for each NHS organisation participating.

 

Series of icons for the services available to patients through MayzentConnect

 

Image of MayzentConnect leaflet

A leaflet with information on MayzentConnect offerings and setting up process.

Preview

 

*These companies have been selected to provide MayzentConnect to you based on their competencies and will adhere to a high standard of practice. You and your MS team retain responsibility for the care of each patient.

MayzentConnect is offered as a package deal, developed and funded by Novartis Pharmaceuticals UK Ltd. MayzentConnect is for NHS patients who are receiving MAYZENT or for whom the prescribing decision has been made. A service level agreement is required for each NHS organisation participating.

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1

MS, multiple sclerosis; SPMS, secondary progressive multiple sclerosis.

Reference

  1. MAYZENT Summary of Product Characteristics.
     
Rate this content: 
Average: 3.2 (9 votes)
UK | February 2022 | 153212
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]